45results about How to "Useful prediction" patented technology

The present invention describes polynucleotides and polypeptides that have been discovered to correlate to the relative intrinsic sensitivity or resistance of cells, e.g., colon cell lines, to treatment with compounds that interact with and inhibit src tyrosine kinases. These polynucleotides and polypeptides have been shown, through a weighted voting cross validation program, to have utility in predicting the intrinsic resistance and sensitivity of colon cell lines to these compounds. Such polynucleotides and polypeptides whose expression levels correlate highly with drug sensitivity or resistance comprise predictor or marker sets of polynucleotides and polypeptides that are useful in methods of predicting drug response, and as prognostic or diagnostic indicators in disease management, particularly in those disease areas in which signaling through src tyrosine kinase of the src tyrosine kinase pathway is involved with the disease process.

The present invention relates generally to methods of in vitro diagnostics, in particular the use of a compound selected from the group consisting of fibroblast growth factor 23 (FGF23), inorganic phosphorus (P), the product of inorganic phosphorus and total calcium (P×tCa), osteopontin (OPN) and parathyroid hormone (PTH) as biomarker. Said biomarkers can be used to monitor the modulation of fibroblast growth factor receptor (FGFR) kinase activity, in particular its inhibition, and/or the occurrence of secondary effects of FGFR inhibition. The invention further provides methods and kits relating to these uses.

The present disclosure includes biomarkers, methods, devices, reagents, systems, and kits for the evaluation of risk of a caradiovascular (CV) Event within 5 years. In one aspect, the disclosure provides biomarkers that can be used alone or in various combinations to evaluate risk of a CV event within 5 years. In another aspect, methods are provided for evaluating risk of a CV event within 5 years in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 1. In a further aspect, methods are provided for evaluating the risk of a CV, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 2. In a further aspect, methods are provided for evaluating the risk of a CV event in an individual, generally within 5 years, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 3.

A novel carbohydrate antigen, β1,4-GalNAc-disialyl-Lc₄, defined by monoclonal antibody RM2, is expressed in human prostate cancer, but not in benign prostate hypertrophy (BPH) or normal prostate gland. Monoclonal antibody RM2 or other antibodies with similar specificity are useful for diagnosis of prostate cancer by immunohistology of biopsy samples, specifications from a total prostatectomy, and quantitative determination of RM2 antigen in sera of patients.

The present invention provides a method of identifying a predictor of antisense oligonucleotide activity by identifying properties of oligonucleotides, evaluating oligonucleotide activity of the oligonucleotides, and correlating oligonucleotide activity with the properties. A high correlation between oligonucleotide activity and a property indicates that the property is a predictor of oligonucleotide activity.

Provided are methods of classifying biological samples based on high dimensional data obtained from the samples. The methods are especially useful for prediction of a class to which the sample belongs under circumstances in which the data are statistically under-determined. The advent of microarray technologies which provide the ability to measure en masse many different variables (such as gene expression) at once has resulted in the generation of high dimensional data sets, the analysis of which benefits from the methods of the present invention. High dimensional data is data in which the number of variables, p, exceeds the number of independent observations (e.g. samples), N, made. The invention relies on a dimension reduction step followed by a logistic determination step. The methods of the invention are applicable for binary (i.e. univariate) classification and multi-class (i.e. multivariate) classifications. Also provided are data selection techniques that can be used in accordance with the methods of the invention.

The invention in some aspects provides methods of determining the likelihood that a subject has lung cancer based on the expression of informative-genes. In other aspects, the invention provides methods for determining an appropriate diagnostic intervention plan for a subject based on the expression of informative-genes. Related compositions and kits are provided in other aspects of the invention.

The invention relates to a computer-aided method for predicting particle uptake by a surface of an object moving in a flow current, comprising the following steps: preparing a discrete model of said object and the surrounding flow, including a projection area (21) for projecting said particles formed by a mesh of cells (23) with an identical size, and a mesh of cells (13) of said surface (11); simulating the projection of particles with a different size from said projection area (21) on the surface (11), both the density Di of projected particles and their size distribution being identical for the cell (23); obtaining for each cell (13) of said surface (11) the local uptake efficiency parameter β by dividing the density Df of particles impacting against said cell (13) by the density Di of particles projected from the projection area (21).

Methods for predicting the likelihood of development of rheumatoid arthritis for individuals that present with recent-onset undifferentiated arthritis. The methods are based on the determination of a set of clinical markers and/or parameters and determining a predicted risk for developing rheumatoid arthritis. Clinical markers and parameters that are decisive for the risk for developing rheumatoid arthritis may include serum levels of C-reactive protein, Rheumatoid factors, anti-CCP antibodies, anti-MCV as well as age, gender, localization of the joint complaints, length of morning stiffness, and number of tender and/or swollen joints or combinations thereof. The method may be performed by a computer. The invention further relates to a computer, a sample analyser and a computer program product for performing the method and a data carrier with the computer program product.

The present invention is directed to methods and compositions for the detection of infection and disease due to members of the genus Mycobacterium. In particular, the present invention is well-suited to the detection and identification of patients with disease or infection due to M. tuberculosis or MAC.

The present invention provides a combination of genes useful for information which can be used for the prediction of postoperative recurrence of gastric cancer and the acquisition of the information, a probe detecting these genes and a primer set for PCR, a method for detecting these genes using the primer and the primer set and a method for obtaining the information which can be used for the prediction of recurrence. Information useful for the prediction of postoperative recurrence can be obtained by determining the presence or absence of gastric cancer cells which show a possibility of postoperative recurrence in a sample such as an peritoneal wash collected from a patient by detecting a particular gene specific to gastric cancer cells or a gene product thereof.

A base-station failure predictor comprises an interface to at least one sub-unit of a base-station of a mobile communications network, an alarm memory, and an alarm evaluator. The base-station failure predictor is adapted to receive a plurality of alarms from the at least one sub-unit of the base-station via the interface. The plurality of alarms are stored in the alarm memory, and the alarm evaluator is adapted to analyze the frequency of the plurality of alarms to assess a likelihood of failure of the at least one sub-unit concerned. A base-station failure prediction method is also proposed. Furthermore, a computer program product with instructions for the manufacture and a computer program product enabling a processor to carry out the base-station prediction method are also proposed.

A method is provided for predicting the structure of a macromolecule by modeling the folding process from the unfolded to the folded state based on machine learning a training set of known structures.

The present invention relates to the analysis of data to identify relationships between the input data and one or more conditions. One method of analysing such data is by the use of neural networks which are non-linear statistical data modelling tools, the structure of which may be changed based on information that is passed through the network during a training phase. A known problem that affects neural networks is the issue of overtraining which arises in overcomplex or overspecified systems when the capacity of the network significantly exceeds the needed parameters. The present invention provides a method of analysing data using a neural network with a constrained architecture that mitigates the problems associated with the prior art.

This invention refers to the field of human medicine and specifically to the diagnosis/prognosis of the responsiveness to a cytokine targeting drug (Cy TD) or an anti-inflammatory biological drug treatment of a subject suffering from an inflammatory disease. More precisely, the present invention concerns a method for the in vitrodiagnosis/prognosis of a Cy TD or an anti-inflammatory biological drug responsive or non-responsive phenotype, comprising: (a) determining from a subject biological sample an expression profile comprising the gene MKNK1; or of the genes MKNK1 and GNLY; or of the genes MKNK1, TBX21 and TGFBR3; or of the genes MKNK1, GNLY, and ADI1; or of the genes MKNK1, GNLY, ADI1, and IL1B; or of the genes MKNK1, GNLY, ADI1, IL1B, and IL1R1; or of the genes MKNK1, PRF1, TBX21, TGFBR3, IFNGR2, FYN, IL1B and CFLAR; or of the genes MKNK1, PRF1, TBX21, TGFBR3, IFNGR2, FYN, IL1B, CFLAR, MAPK14 and GNLY; or of the genes MKNK1, PRF1, TBX21, TGFBR3, IFNGR2, FYN, IL1B, CFLAR, CD14 and TGFBR2; or of the genes MKNK1, IFNGR2, IL1B, MAPK14, GNLY, and CD14; or of the genes MKNK1, PRF1, TBX21, TGFBR3, IFNGR2, IL1B, CFLAR, MAPK14, GNLY, CD14 and TGFBR2; or of all the 46 genes of following Tables 2, 3 and 4; or Equivalent Expression Profile thereof, provided that, in said Equivalent Expression Profile thereof, MKNK1 is not replaced by gene S 100A8 nor gene MAPK14, and (ii) optionally one or more housekeeping gene(s), (b) comparing the obtained expression profile with at least one reference expression profile, and (c) determining the responsive or non-responsive phenotype from said comparison. The present invention also relates to kits and nucleic acid microarrays for performing said method. The present invention also relates to methods of treatment of inflammatory disease-suffering patients.

Methods and kits for detecting polymorphism that are predictive of a subject's susceptibility to developing sepsis are described.

The disclosed methods and systems are generally directed to the combined application of predictive analytics with clinical decision analysis to provide optimal recommendations for the implementation of various health care management programs including, for example, prescription medication adherence interventions, and providing recommendations for medication adherence interventions for individual patients, based on predictions of patient adherence and predicted or expected responses to available interventions. Such interventions may be instituted in advance of a potential negative outcome, e.g., non-adherence, to prevent or reduce the occurrence of a negative outcome and realize greater return on investment. The disclosed systems and methods generally determine a predictive function based at least on historical patient data and predictive variables derived from the historical data, apply the predictive function to data of candidate patients and provide a recommended course of health care management based on an output of the predictive function applied to a clinical decision analysis.

The invention provides an in vitro method for predicting whether a patient would be responsive to a treatment with a TNFα blocking agent, which method comprises determining the expression level of eight genes in a biological sample of said patient, wherein said genes are EPS15, HLA-DPB1, AKAP9, RASGRP3, MTCBP-1, PTNP12, MRPL22 and RPS28. The invention further provides a DNA chip for performing such method.

This invention relates to a composition and a method for prediction of a response to Trastuzumab therapy in a breast cancer patient, and more specifically, a composition, a kit, a DNA chip, and a method for predicting a response to Trastuzumab therapy by using polynucleotides each comprising a nucleotide sequence represented by any of SEQ ID NOs: 1 to 9, 11 to 19, and 21 to 23 in the Sequence Listing or a nucleotide sequence derived therefrom by substitution of u with t, mutants thereof, derivatives thereof, or fragments thereof comprising at least 16 continuous nucleotides, or a polynucleotide comprising a complementary sequence thereof, and using an increase or decrease in Her2 protein expression level as an indicator.

The invention provides an ex vivo method for detecting the risk of cancer in a patient, comprising the step of: (iii) detecting the expression level of the genes identified herein as ELN, RGS-1, SOCS-3, PTGS-2, JUN, ATF-3, CTGF, IGF-2 and RBMS-1, in a sample of genetic material isolated from a patient, wherein the combined expression level indicates the risk of cancer in the patient from whom the sample was isolated.

An object of the present invention is to provide a probe, primer, primer set and antibody for determining neonatal alloimmune thrombocytopenic purpura or the risk of developing it. According to the present invention, there is provided a probe, primer, primer set and antibody for use in the detection of the thymine residue at position 1297 in the GPIIIa.